# Choledocholithiasis

Manage suspected common bile duct stones by separating patients needing urgent biliary drainage from those needing risk-stratified confirmation, reserving ERCP for therapeutic intent, and ensuring gallbladder-source control after duct clearance when surgery is feasible.

**Clinical question:** How should physicians confirm, clear, and prevent recurrence of suspected common bile duct stones?

Updated: 2026-09-16T00:48:52.377932+00:00

## What matters in practice
- Clinical ascending cholangitis or a common bile duct stone visualized on ultrasonography are high-probability findings and should direct patients toward therapeutic biliary intervention rather than diagnostic ERCP. [4][13]
- For intermediate-risk suspected choledocholithiasis, confirm ductal stones with EUS or MRCP; intraoperative cholangiography is another operative-pathway option. [13][16]
- ERCP should principally be used for stone extraction or drainage because diagnostic ERCP can cause serious adverse events. [6]
- Persistent suspicion after a negative MRCP warrants EUS consideration, particularly when total bilirubin exceeds 3 mg/dL; 15% of one such intermediate-risk cohort had a positive EUS. [7]
- After endoscopic duct clearance in a patient with concomitant gallbladder stones who can undergo surgery, perform early laparoscopic cholecystectomy, ideally within 72 hours after ERCP. [18]

## Identify patients who need biliary drainage rather than further stone testing

The first branch is obstruction with cholangitis versus stable suspected ductal stone disease.

Clinical ascending cholangitis is a high-probability predictor of choledocholithiasis, with reported specificity of 99% to 100%; a stone seen on transabdominal ultrasonography is likewise highly specific (94% to 97%). Either finding supports proceeding to biliary therapy rather than obtaining confirmatory MRCP or EUS solely to establish the diagnosis. [4]

In a patient with suspected choledocholithiasis and clinical cholangitis, prioritize early antibiotic therapy and rapid biliary drainage. ERCP provides both cholangiographic confirmation and endoscopic sphincterotomy with stone extraction or drainage; if endoscopic treatment fails, cholecystectomy with bile duct exploration or intraoperative ERCP is an alternative pathway. [18][23]

Do not use ERCP as a default diagnostic test in stable patients without a therapeutic indication. Its diagnostic role has been displaced by EUS and MRCP because ERCP is invasive, technically challenging, and can produce serious adverse events even in experienced hands. [6]
- Visible duct stone on ultrasonography: treat as high probability and arrange therapeutic ERCP or surgical duct clearance according to local expertise. [4][5]
- Clinical ascending cholangitis: initiate urgent biliary-drainage pathway rather than a sequential outpatient imaging pathway. [4][23]
- Stable patient without definitive high-probability findings: assign a pretest-risk group before selecting EUS, MRCP, intraoperative cholangiography, or cholecystectomy. [13][16]

*Initial management branch for suspected choledocholithiasis. [4][13][16][23]*

| Clinical branch | Actionable finding | Next step |
| --- | --- | --- |
| Suspected cholangitis | Clinical ascending cholangitis; highly specific for duct stones. [4] | Give early antibiotics and arrange rapid biliary drainage, usually therapeutic ERCP. [23] |
| Definite duct stone | Stone visualized on transabdominal ultrasonography. [4] | Proceed to duct clearance by ERCP or surgery without confirmatory diagnostic ERCP. [5] |
| Stable uncertain diagnosis | No cholangitis and no stone directly identified. [13] | Use ASGE-style risk stratification; intermediate-risk patients undergo EUS or MRCP. [13][16] |

## Use pretest probability to choose EUS, MRCP, or operative cholangiography

Risk stratification is intended to avoid unnecessary ERCP while preserving timely stone clearance.

The ASGE framework categorizes suspected choledocholithiasis as low risk (<10%), intermediate risk (10% to 50%), or high risk (>50%). The 2019 update emphasizes reducing unnecessary ERCP; low-risk patients proceed to cholecystectomy, intermediate-risk patients receive confirmatory biliary imaging, and high-risk patients proceed to ERCP or another duct-clearance strategy. [13][16]

For intermediate-risk patients, choose EUS or MRCP based on local availability, need for same-session endoscopic therapy, contraindications to MRI, and concern for small stones. ASGE suggests either EUS or MRCP for confirmation; systematic-review data indicate broadly comparable diagnostic performance, while EUS may better identify stones smaller than 3 mm. [8][13][16]

Transabdominal ultrasonography remains useful for gallstones, ductal dilation, and directly seen duct stones, but it is substantially less sensitive than MRCP in one direct-comparison study (38% versus 91%) despite 100% specificity. A negative ultrasound therefore does not exclude choledocholithiasis when bilirubin abnormalities, persistent pain, or ductal dilation maintain intermediate clinical probability. [22]

After a negative MRCP, do not reflexively dismiss a persistent clinical concern. In an intermediate-risk cohort selected for continued pain or abnormal liver enzymes, EUS identified choledocholithiasis in 15% (23 of 153), with ERCP confirmation of sludge or stones in 21 patients; total bilirubin above 3 mg/dL particularly supported considering EUS. [7]
- Low risk (<10%): proceed with cholecystectomy rather than preoperative ERCP. [13][16]
- Intermediate risk (10% to 50%): obtain EUS or MRCP; intraoperative cholangiography is an alternative when proceeding directly to surgery. [13][16]
- High risk (>50%): proceed to endoscopic or surgical duct clearance, but recognize that selected patients with dilated duct and bilirubin 1.8 to 4 mg/dL may benefit from EUS first when there is no severe cholangitis or definite cross-sectional-imaging stone. [6][13]
- Negative MRCP with ongoing pain or liver-test abnormality: consider EUS, especially if total bilirubin is >3 mg/dL. [7]

### EUS-first versus ERCP-first in selected high-risk patients

A prospective multicenter study enrolled patients with a dilated common bile duct and total bilirubin of 1.8 to 4 mg/dL, excluding severe cholangitis and visible stones on cross-sectional imaging. In this selected group, EUS first reduced diagnostic ERCP and endoscopy-related hospital stay, although it did not significantly reduce negative endoscopic-procedure outcomes. Use this strategy when the apparent high-risk classification is driven by duct dilation plus modest hyperbilirubinemia rather than definitive cholangitis or imaging-proven stone. [6]

*Risk-based diagnostic selection for suspected common bile duct stones. [6][7][8][13][16][22]*

| Risk or scenario | Preferred test or pathway | Result that changes management |
| --- | --- | --- |
| Low risk, <10% | Cholecystectomy without preoperative ERCP. [13][16] | Intraoperative suspicion or cholangiographic stone redirects to duct clearance. [16] |
| Intermediate risk, 10% to 50% | EUS or MRCP; consider intraoperative cholangiography if proceeding to surgery. [13][16] | Confirmed stone directs therapeutic ERCP or operative bile duct exploration. [5][13] |
| Negative ultrasound but persistent suspicion | MRCP or EUS rather than reassurance from ultrasound alone. [22] | MRCP has reported sensitivity of 91% versus 38% for ultrasound in a direct comparison. [22] |
| Negative MRCP with continuing symptoms or abnormal liver enzymes | EUS, particularly with total bilirubin >3 mg/dL. [7] | EUS was positive in 15% of this selected intermediate-risk cohort. [7] |
| Dilated duct plus bilirubin 1.8-4 mg/dL, no severe cholangitis or visible stone | Consider EUS first rather than ERCP first. [6] | A negative EUS can avoid diagnostic ERCP; a positive EUS directs therapeutic ERCP. [6] |

## Clear confirmed stones with ERCP or laparoscopic bile duct exploration

Select the duct-clearance route by acuity, anatomy, surgical capability, and coordination with cholecystectomy.

For confirmed choledocholithiasis, standard endoscopic treatment is ERCP with biliary sphincterotomy and stone extraction using balloon catheters or baskets; more than 90% of common bile duct stones can reportedly be managed by endoscopic sphincterotomy and extraction. Endoscopic papillary balloon dilation is also an emphasized technique in the updated ASGE guidance. [1][11]

Laparoscopic common bile duct exploration with cholecystectomy is a valid one-stage alternative where expertise and equipment are available. Compared with ERCP-based management, it avoids post-ERCP pancreatitis but requires advanced laparoscopic skill and can cause bile leakage; the choice should therefore reflect local procedural competence and the anticipated need for definitive gallbladder surgery. [2][19]

When ductal stones are discovered intraoperatively, clearance can be attempted by transcystic access or direct choledochotomy, with intraoperative contrast cholangiography documenting clearance. Surgical exploration is particularly relevant after failed endoscopic therapy or where a coordinated one-stage surgical approach is available. [18][19]

For residual stones detected after cholecystectomy, ERCP with extraction is the reference approach. If ERCP cannot clear the duct, escalate to surgical bile duct exploration or intraoperative ERCP rather than leaving a confirmed obstructing stone untreated. [18][23]
- ERCP route: sphincterotomy plus balloon or basket extraction for confirmed duct stones. [11]
- One-stage operative route: laparoscopic cholecystectomy plus bile duct exploration when local expertise supports transcystic or choledochotomy clearance. [2][19]
- Failed ERCP: use surgical bile duct exploration or intraoperative ERCP. [18]
- Post-cholecystectomy residual duct stone: perform ERCP extraction. [23]

*Duct-clearance approaches and operational tradeoffs. [2][11][18][19][23]*

| Approach | Best-fit setting | Key tradeoff or escalation |
| --- | --- | --- |
| ERCP with sphincterotomy and extraction | Confirmed duct stone requiring endoscopic clearance or drainage. [11] | Effective in >90% in reported practice; ERCP carries risks including post-ERCP pancreatitis. [2][11] |
| Laparoscopic bile duct exploration with cholecystectomy | Patient already undergoing cholecystectomy in a center with advanced laparoscopic capability. [2][19] | May avoid post-ERCP pancreatitis but requires specialized skill and may cause bile leakage. [2] |
| Intraoperative ERCP | Failed preoperative endoscopic therapy or coordinated single-session management. [18] | Provides an alternative duct-clearance route when standard endoscopic therapy is unsuccessful. [18] |
| ERCP after cholecystectomy | Residual common bile duct stone detected postoperatively. [23] | Reference treatment for extraction of residual stones. [23] |

## Perform early cholecystectomy after duct clearance when the gallbladder remains in situ

Endoscopic clearance treats the ductal event but does not remove the gallbladder source.

For patients with simultaneous gallbladder and common bile duct stones who are operative candidates, perform laparoscopic cholecystectomy early after preoperative ERCP—within 72 hours in EASL guidance. This timing is associated with fewer recurrent biliary events than delayed surgery. [18]

Avoid treating placement of a plastic biliary stent as a benign bridge to elective surgery. In a 2025 study of patients awaiting cholecystectomy after ERCP for common bile duct stones, plastic stenting for initial treatment independently increased biliary-tract events during the waiting period (odds ratio 4.25). [11]

When surgery is not feasible, endoscopic sphincterotomy alone can reduce recurrent biliary pancreatitis but leaves a substantial burden of other biliary events. Across eight case series totaling 320 patients managed with sphincterotomy alone and gallbladder left in situ, recurrent biliary pancreatitis occurred in 1%, but 17% developed biliary symptoms or complications such as cholecystitis or biliary colic. [24]
- Gallbladder and duct stones, surgical candidate: schedule laparoscopic cholecystectomy within 72 hours after ERCP duct clearance. [18]
- Biliary stent placed pending surgery: minimize delay and monitor for recurrent cholecystitis, cholangitis, or need for unplanned ERCP. [11]
- Nonoperative patient: endoscopic sphincterotomy alone is a compromise strategy, not equivalent gallbladder-source control. [24]

*Post-clearance management when gallbladder stones coexist. [11][18][24]*

| Patient status | Recommended next step | Reason |
| --- | --- | --- |
| Fit for surgery after ERCP stone extraction | Laparoscopic cholecystectomy within 72 hours. [18] | Early surgery reduces recurrent biliary events compared with delayed cholecystectomy. [18] |
| Plastic stent used while awaiting cholecystectomy | Expedite definitive surgery and reassess promptly for biliary events. [11] | Plastic stenting was associated with increased waiting-period biliary events (OR 4.25). [11] |
| Not fit for cholecystectomy | Consider endoscopic sphincterotomy as the nonoperative alternative. [24] | Recurrent pancreatitis was uncommon in case series, but 17% developed other biliary symptoms or complications. [24] |

## Avoid diagnostic ERCP and escalate unresolved obstruction

The key errors are under-testing intermediate-risk patients and delaying source control after clearance.

Do not equate a negative CT or ultrasound with ductal clearance in a patient whose clinical probability remains intermediate or high. In a cohort of patients with suspected choledocholithiasis, stones were found at ERCP in 40.6% of intermediate-risk patients and 65.9% of high-risk patients; a negative cross-sectional study should be interpreted alongside the pretest-risk category and ongoing biochemical or clinical evidence of obstruction. [5]

For high-probability patients without cholangitis or a definite stone on cross-sectional imaging, the probability of actual choledocholithiasis may be only slightly above 50%; EUS first can reduce avoidable diagnostic ERCP in the subgroup defined by ductal dilation and bilirubin 1.8 to 4 mg/dL. [6]

After a negative MRCP, persistent abdominal pain or abnormal liver enzymes should trigger reassessment rather than automatic discharge from the duct-stone pathway. EUS can detect small stones that MRCP may miss and produced clinically actionable findings in the selected cohort described above. [7][8]
- Escalate from negative MRCP to EUS when suspicion persists, especially with bilirubin >3 mg/dL. [7]
- Use ERCP after confirmation by EUS or MRCP in stable intermediate-risk patients, preserving ERCP for extraction or drainage. [6][13]
- If endoscopic clearance fails, refer for operative bile duct exploration or intraoperative ERCP. [18]

*Common decision traps in suspected choledocholithiasis. [5][6][7][8][18]*

| Trap | Why it matters | Corrective action |
| --- | --- | --- |
| Diagnostic ERCP for intermediate probability | ERCP can cause serious adverse events. [6] | Confirm with EUS or MRCP before ERCP. [13][16] |
| Reassurance after negative ultrasound | Ultrasound sensitivity was 38% in one direct comparison. [22] | Obtain EUS or MRCP when the clinical probability remains intermediate. [13][16] |
| Reassurance after negative MRCP despite ongoing concern | EUS found stones in 15% of a selected negative-MRCP cohort. [7] | Use EUS when symptoms or liver-test abnormalities persist; bilirubin >3 mg/dL strengthens the case. [7] |
| Delayed cholecystectomy after duct clearance | Persistent gallbladder stones permit recurrent biliary events. [18] | Perform early laparoscopic cholecystectomy within 72 hours when feasible. [18] |

## References
1. Updated ASGE Guideline on Management of Choledocholithiasis | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/updated-asge-guideline-management-choledocholithiasis-nejm-jw.NA48954
2. Safety and effectiveness of modified laparoscopic transcystic biliary drainage in the treatment of choledocholithiasis: study protocol for a prospective single-arm clinical trial — bmjopen.bmj.com — https://bmjopen.bmj.com/content/15/4/e089540
3. Comparing diagnostic accuracy of current practice guidelines in predicting choledocholithiasis: outcomes from a large healthcare system comprising both academic and community settings - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0016510720349397
4. Accuracy of ASGE high-risk criteria in evaluation of patients with suspected common bile duct stones - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0016510717300834
5. Diagnostic performance of the current risk-stratified approach with computed tomography for suspected choledocholithiasis and its options when negative finding - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1499387219301286
6. Role of EUS at high risk for choledocholithiasis... : Endoscopic Ultrasound — journals.lww.com — https://journals.lww.com/eusjournal/fulltext/2021/10060/role_of_eus_at_high_risk_for_choledocholithiasis.9.aspx
7. EUS assessment for intermediate risk of choledocholithiasis ... : Endoscopic Ultrasound — journals.lww.com — https://journals.lww.com/eusjournal/fulltext/2020/09050/eus_assessment_for_intermediate_risk_of.9.aspx
8. Endoscopic ultrasonography versus magnetic resonance... : Endoscopic Ultrasound — journals.lww.com — https://journals.lww.com/eusjournal/fulltext/2016/05020/endoscopic_ultrasonography_versus_magnetic.10.aspx
9. 24 A Comparison of EUS and MRCP to Diagnose... : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/fulltext/10.14309/01.ajg.0000589628.73334.cf~24a-comparison-of-eus-and-mrcp-to-diagnose
10. EUS vs MRCP for detection of choledocholithiasis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0016510706001416
11. Risk factors for biliary tract events during elective cholecystectomy waiting time after endoscopic retrograde cholangiopancreatography for choledocholithiasis - Satoh - 2025 - DEN Open - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/deo2.409
12. Giant Primary Choledocholithiasis: A Rare Case Report and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.9720
13. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8594622
14. Endoscopic Retrograde Cholangiopancreatography - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK493160
15. Evidence-based clinical practice guidelines for cholelithiasis 2021 — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10423145
16. Intermediate risk of choledocholithiasis: are we on the right path? - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10129273
17. A clinician's guide to gallstones and common bile duct (CBD) - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10496460
18. [PDF] EASL Clinical Practice Guidelines on the prevention, diagnosis and ... — easl.eu — https://easl.eu/wp-content/uploads/2016/10/EASL-CPG-Gallstones.pdf
19. T-Tube - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK532867
20. Choledocholithiasis: evaluation of MR cholangiography for diagnosis. — pubs.rsna.org — https://pubs.rsna.org/doi/full/10.1148/radiology.209.2.9807570
21. Choledocholithiasis: comparison of MR cholangiography and ... — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/radiology.200.1.8657949
22. The diagnostic accuracy of magnetic resonance cholangiopancreatography and ultrasound compared with direct cholangiography in the detection of choledocholithiasis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0009926099900235
23. Management of common bile duct stones (choledocholithiasis) and its complications (part 2) — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1878788626000755
24. Management of gallstone pancreatitis: Cholecystectomy or ERCP and endoscopic sphincterotomy - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0016510702000081

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.